Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
Relay Therapeutics reported positive Phase 1/2 data for its zovegalisib triplet combination, showing a 44% objective response rate in heavily pre-treated, median third-line metastatic breast cancer patients. Based on the tolerability and efficacy profile, the company plans to advance the regimen into a randomized Phase 3 trial for frontline patients, expected to initiate in early 2027.
Key figures
- Drug Name
- zovegalisib
- Phase Of Trial
- Phase 1/2
- Median follow up months
- 7.4
- Patients at or below rp3d
- 62
- Patients evaluated for response
- 34
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.